Moisa I I
Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Head Neck. 1991 Nov-Dec;13(6):498-508. doi: 10.1002/hed.2880130605.
A review of the international literature has revealed 68 paragangliomas, 42 large cell, and 74 small cell tumors of the larynx. Paragangliomas are usually benign, although malignant cases have been reported. Large cell tumors are malignancies associated with a high incidence of early cervical metastasis. Small cell tumors are aggressive cancers characterized by early, diffuse metastatic disease. All three neoplasms demonstrate a propensity for the supraglottic larynx. While surgery remains the treatment of choice for paragangliomas and large cell cancers, small cell cancers are best treated by radiotherapy and chemotherapy. The determinate 5-year survival for patients with paragangliomas, large cell, and small cell cancers is 60%, 34%, and 14%, respectively. While representing distinct clinical entities, these neoplasms demonstrate similar ultrastructural and histochemical features and should be classified as neuroendocrine tumors of the larynx (NETL). A comprehensive analysis of these laryngeal tumors is presented herein. Their clinical behavior and management options are reviewed and a scheme for their nomenclature and classification is proposed.
对国际文献的回顾显示，有68例副神经节瘤、42例大细胞型和74例小细胞型喉肿瘤。副神经节瘤通常为良性，不过也有恶性病例的报道。大细胞型肿瘤是恶性肿瘤，早期颈部转移发生率很高。小细胞型肿瘤是侵袭性癌症，其特征为早期出现弥漫性转移疾病。这三种肿瘤均显示出累及声门上区喉的倾向。虽然手术仍然是副神经节瘤和大细胞型癌症的首选治疗方法，但小细胞型癌症最好采用放疗和化疗。副神经节瘤、大细胞型和小细胞型癌症患者的5年确定生存率分别为60%、34%和14%。虽然这些肿瘤代表不同的临床实体，但它们显示出相似的超微结构和组织化学特征，应归类为喉神经内分泌肿瘤（NETL）。本文对这些喉肿瘤进行了全面分析。回顾了它们的临床行为和治疗选择，并提出了它们的命名和分类方案。
